Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium  Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 49, 3242-3245, June 15, 1989]
© 1989 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dale, I. L.
Right arrow Articles by Pettit, G. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dale, I. L.
Right arrow Articles by Pettit, G. R.

Comparison of Effects of Bryostatins 1 and 2 and 12-O-Tetradecanoylphorbol-13-acetate on Protein Kinase C Activity in A549 Human Lung Carcinoma Cells1

Ian L. Dale, Tracey D. Bradshaw, Andreas Gescher2 and George R. Pettit

Cancer Research Campaign Experimental Chemotherapy Group, Pharmaceutical Sciences Institute, Aston University, Birmingham B4 7ET, England [I. L. D., T. D. B., A. G.], and Cancer Research Institute, Arizona State University, Tempe [G. R. P.], Arizona 85287

Activators of protein kinase C (PKC), such as 12-O-tetradecanoylphorbol-13-acetate (TPA) and bryostatins 1 and 2, inhibit the growth of A549 cells. At high concentrations the bryostatins do not affect cell growth. Here the hypothesis has been tested that modulation of A549 cell growth is the consequence of agent-induced changes in location or extent of cellular PKC activity. PKC activity was measured after semipurification with nondenaturing polyacrylamide gel electrophoresis in the cytosol and the particulate fraction of A549 cells. When cells were exposed to TPA or mezerein, PKC activity underwent rapid and concentration-dependent translocation from the cytosol to the membrane. TPA at 0.1 µM or mezerein at 1 µM caused almost complete translocation within 30 min. Incubation with bryostatins 1 or 2 also led to enzyme translocation, which was, however, much weaker than that observed with the tumor promoters. Neither 4{alpha}-phorboldidecanoate nor the synthetic diacylglycerols 1,2-sn-dioctanoylglycerol or 1-oleoyl-2-acetyl-sn-glycerol mimicked TPA in this way. Exposure of cells to TPA or the bryostatins for longer than 30 min caused the gradual disappearance of total cellular PKC activity. PKC downregulation was concentration dependent and complete after 24 h. A549 cells which had acquired temporary resistance toward the growth-arresting potential of TPA were completely devoid of any measurable PKC activity. The bryostatins were potent inhibitors of the binding of [3H]phorbol-12,13-dibutyrate to its receptors in intact cells, and the inhibition was dependent on bryostatin concentration. The results support the contention that PKC is involved in the mediation of growth inhibition caused by TPA or the bryostatins. However, the relationship between growth arrest and PKC translocation or downregulation seems to be a complex one.

1 Supported by Grant SP 1518 from the Cancer Research Campaign of Great Britain. The isolation of the bryostatins was funded by NIH Grant CA 16049, the Fannie E. Rippel Foundation, the Arizona Disease Control Research Commission, and the Robert B. Dalton Endowment Fund.

2 To whom requests for reprints should be addressed.

Received 12/ 5/88. Revised 3/ 6/89. Accepted 3/14/89.




This article has been cited by other articles:


Home page
Molecular Cancer TherapeuticsHome page
J. R. Stewart and C. A. O'Brian
Protein kinase C-{alpha} mediates epidermal growth factor receptor transactivation in human prostate cancer cells
Mol. Cancer Ther., May 1, 2005; 4(5): 726 - 732.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
N. B. Haas, M. Smith, N. Lewis, L. Littman, G. Yeslow, I. D. Joshi, A. Murgo, J. Bradley, R. Gordon, H. Wang, et al.
Weekly Bryostatin-1 in Metastatic Renal Cell Carcinoma: A Phase II Study
Clin. Cancer Res., January 1, 2003; 9(1): 109 - 114.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
R. E. Curiel, C. S. Garcia, L. Farooq, M. F. Aguero, and I. Espinoza-Delgado
Bryostatin-1 and IL-2 Synergize to Induce IFN-{gamma} Expression in Human Peripheral Blood T Cells: Implications for Cancer Immunotherapy
J. Immunol., November 1, 2001; 167(9): 4828 - 4837.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1989 by the American Association for Cancer Research.